<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807283</url>
  </required_header>
  <id_info>
    <org_study_id>CL-0017</org_study_id>
    <nct_id>NCT04807283</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System</brief_title>
  <official_title>A European Trial Evaluating the Safety and Effectiveness of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laminar, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laminar, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to demonstrate safety and effectiveness using a percutaneous&#xD;
      Delivery System of the Laminar Left Atrial Appendage Closure System to treat patients with&#xD;
      NVAF to reduce the risk of thromboembolism from the left atrial appendage (LAA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device or procedure related serious adverse events</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmation of functional LAA closure as defined by residual peri-device flow ≤ 5mm per TEE</measure>
    <time_frame>45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of all-cause mortality, major bleeding, ischemic stroke, or systemic embolism</measure>
    <time_frame>45 days and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left Atrial Appendage Closure</intervention_name>
    <description>Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Left Atrial Appendage Occlusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subject must have a documented history of paroxysmal, persistent or permanent&#xD;
             nonvalvular atrial fibrillation (AF).&#xD;
&#xD;
          -  2. Subject must be ≥18 years of age.&#xD;
&#xD;
          -  3. Subject has a calculated CHA2DS2-VASc score of 2 or greater.&#xD;
&#xD;
          -  4. Subject must be clinically stable on warfarin (or other anticoagulant) therapy for&#xD;
             a minimum of three months.&#xD;
&#xD;
          -  5. Subject must have at least two International Normalized Ratios (INRs); 2-3, if on&#xD;
             Warfarin.&#xD;
&#xD;
          -  6. Subject is eligible for the defined protocol pharmacologic regimen of&#xD;
             anticoagulation and antiplatelet therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subject who requires anticoagulation for a condition other than AF.&#xD;
&#xD;
          -  2. Subject with a New York Heart Association (NYHA) classification equal to IV.&#xD;
&#xD;
          -  3. Subject with a history of or implanted atrial septal defect (ASD) device or patent&#xD;
             foramen ovale (PFO) device that would interfere with the investigational device&#xD;
             placement.&#xD;
&#xD;
          -  4. Subject with valvular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lolitha Brown</last_name>
    <phone>7072179541</phone>
    <email>lbrown@laminarlaa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Israeli-Georgian Medical Research Clinic Helsicore</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irakli Gogorishvili, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamaz Shaburishvili, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Atrial Appendage Closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

